radiochemotherapy-Assistance Publique - Hôpitaux de Paris-rectal cancer

This refers to the preoperative radiochemotherapy regimen utilized in the NORAD01-GRECCAR16 (FRENCH-GRECCAR-PRODIGE) phase III clinical trial sponsored by Assistance Publique - Hôpitaux de Paris. The regimen consists of concurrent capecitabine (825 mg/m²/12h, 5 days/week) and intensity-modulated radiation therapy (IMRT) (45-50 Gy). It is being evaluated as part of a total neoadjuvant therapy (TNT) approach or as a comparator to chemotherapy alone (modified FOLFIRINOX) for the treatment of locally advanced resectable rectal cancer. The goal of the radiochemotherapy component is to provide local control and sensitize the tumor to radiation through the action of the fluoropyrimidine capecitabine.

Brand names

Xeloda

Other names

Cap50Cap-50Cap 50capecitabine-based chemoradiotherapypreoperative radiochemotherapyCap50 intensified-modulated radiotherapy with capecitabineCap-50 intensified-modulated radiotherapy with capecitabineCap 50 intensified-modulated radiotherapy with capecitabine